4.5 Article

Subviral particle as vaccine and vaccine platform

Journal

CURRENT OPINION IN VIROLOGY
Volume 6, Issue -, Pages 24-33

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2014.02.009

Keywords

-

Categories

Funding

  1. National Institutes of Health [R01AI089634, P01 HD13021, R21AI092434]
  2. Department of Agricultures of the United States of America (NIFA, AFRI)
  3. institutional Clinical and Translational Science Award [NIH/NCRR 8UL1TR000077-04]

Ask authors/readers for more resources

Recombinant subvirual particles retain similar antigenic features of their authentic viral capsids and thus have been applied as nonreplicating subunit vaccines against viral infection and illness. Additionally, the self-assembled, polyvalent subviral particles are excellent platforms to display foreign antigens for immune enhancement for vaccine development. These subviral particle-based vaccines are noninfectious and thus safer than the conventional live attenuated and inactivated vaccines. While several VLP vaccines are available in the markets, numerous others, including dual vaccines against more than one pathogen, are under clinical or preclinical development. This article provides an update of these efforts.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available